BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magaña-Maldonado R, Chávez-Cortez EG, Olascoaga-Arellano NK, López-Mejía M, Maldonado-Leal FM, Sotelo J, Pineda B. Immunological Evasion in Glioblastoma. Biomed Res Int 2016;2016:7487313. [PMID: 27294132 DOI: 10.1155/2016/7487313] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara CM, Placantonakis DG, Bruno B. Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors. Cancers 2022;14:5108. [DOI: 10.3390/cancers14205108] [Reference Citation Analysis]
2 Singh M, Raghav A, Gautam KA. Role of the circulatory interleukin-6 in the pathogenesis of gliomas: A systematic review. World J Methodol 2022; 12(5): 428-437 [DOI: 10.5662/wjm.v12.i5.428] [Reference Citation Analysis]
3 Petrovic M, Porcello A, Tankov S, Majchrzak O, Kiening M, Laingoniaina AC, Jbilou T, Walker PR, Borchard G, Jordan O. Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors. Pharmaceutics 2022;14:1883. [DOI: 10.3390/pharmaceutics14091883] [Reference Citation Analysis]
4 Wang G, Wang J, Niu C, Zhao Y, Wu P. Neutrophils: New Critical Regulators of Glioma. Front Immunol 2022;13:927233. [DOI: 10.3389/fimmu.2022.927233] [Reference Citation Analysis]
5 Liu B, Ji Q, Cheng Y, Liu M, Zhang B, Mei Q, Liu D, Zhou S. Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM. J Nanobiotechnology 2022;20:161. [PMID: 35351131 DOI: 10.1186/s12951-022-01360-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Exley MA, Garcia S, Zellander A, Zilberberg J, Andrews DW. Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma. J Clin Med 2022;11:1069. [PMID: 35207340 DOI: 10.3390/jcm11041069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Padmakumar S, Huang D, Parayath N, Milane L, Amiji MM. Local and systemic delivery strategies for glioma immunotherapy. Systemic Drug Delivery Strategies 2022. [DOI: 10.1016/b978-0-323-85781-9.00012-9] [Reference Citation Analysis]
8 Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The Interplay between Glioblastoma and Its Microenvironment. Cells 2021;10:2257. [PMID: 34571905 DOI: 10.3390/cells10092257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
9 Arcos-Montoya D, Wegman-Ostrosky T, Mejía-Pérez S, De la Fuente-Granada M, Camacho-Arroyo I, García-Carrancá A, Velasco-Velázquez MA, Manjarrez-Marmolejo J, González-Arenas A. Progesterone Receptor Together with PKCα Expression as Prognostic Factors for Astrocytomas Malignancy. Onco Targets Ther 2021;14:3757-68. [PMID: 34168461 DOI: 10.2147/OTT.S280314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Qiu R, Zhong Y, Li Q, Li Y, Fan H. Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors. Front Cell Dev Biol 2021;9:693215. [PMID: 34211978 DOI: 10.3389/fcell.2021.693215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
11 Handoko, Wahyudi ST, Setiawan AA, Kartono A. A Dynamic Model of Glioma Tumor Growth Based on Changes in Blood Glucose Concentration using Runge-Kutta Order 45. J Phys : Conf Ser 2021;1951:012062. [DOI: 10.1088/1742-6596/1951/1/012062] [Reference Citation Analysis]
12 Zhao WJ, Ou GY, Lin WW. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Front Immunol 2021;12:682415. [PMID: 34054873 DOI: 10.3389/fimmu.2021.682415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
13 Yang YP, Chien CS, Yarmishyn AA, Chan MS, Lee AC, Chen YW, Huang PI, Ma HI, Lo WL, Chien Y, Lin WC, Wang ML, Chen MT. Musashi-1 Regulates MIF1-Mediated M2 Macrophage Polarization in Promoting Glioblastoma Progression. Cancers (Basel) 2021;13:1799. [PMID: 33918794 DOI: 10.3390/cancers13081799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Fanelli GN, Grassini D, Ortenzi V, Pasqualetti F, Montemurro N, Perrini P, Naccarato AG, Scatena C. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes (Basel) 2021;12:445. [PMID: 33804731 DOI: 10.3390/genes12030445] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 29.0] [Reference Citation Analysis]
15 Kazim SF, Martinez E, Hough TJ, Spangler BQ, Bowers CA, Chohan MO. The Survival Benefit of Postoperative Bacterial Infections in Patients With Glioblastoma Multiforme: Myth or Reality? Front Neurol 2021;12:615593. [PMID: 33613432 DOI: 10.3389/fneur.2021.615593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Panzarini E, Tacconi S, Carata E, Mariano S, Tata AM, Dini L. Molecular Characterization of Temozolomide-Treated and Non Temozolomide-Treated Glioblastoma Cells Released Extracellular Vesicles and Their Role in the Macrophage Response. Int J Mol Sci 2020;21:E8353. [PMID: 33171763 DOI: 10.3390/ijms21218353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Yalcin F, Dzaye O, Xia S. Tenascin-C Function in Glioma: Immunomodulation and Beyond. Adv Exp Med Biol 2020;1272:149-72. [PMID: 32845507 DOI: 10.1007/978-3-030-48457-6_9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
18 Holst CB, Christensen IJ, Skjøth-Rasmussen J, Hamerlik P, Poulsen HS, Johansen JS. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Front Oncol 2020;10:478. [PMID: 32363159 DOI: 10.3389/fonc.2020.00478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Kaminska B, Ciechomska I, Cyranowski S. Autophagy in brain tumor immune evasion and responses to immunotherapy. Autophagy in Immune Response: Impact on Cancer Immunotherapy 2020. [DOI: 10.1016/b978-0-12-819609-0.00003-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vidyarthi A, Agnihotri T, Khan N, Singh S, Tewari MK, Radotra BD, Chatterjee D, Agrewala JN. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. Cancer Immunol Immunother 2019;68:1995-2004. [PMID: 31690954 DOI: 10.1007/s00262-019-02423-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
21 González-Morales A, Lachén-Montes M, Fernández-Irigoyen J, Santamaría E. Monitoring the Cerebrospinal Fluid Cytokine Profile Using Membrane-Based Antibody Arrays. Methods Mol Biol 2019;2044:233-46. [PMID: 31432416 DOI: 10.1007/978-1-4939-9706-0_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Graner MW. Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence. Annu Rev Genomics Hum Genet 2019;20:331-57. [PMID: 30978305 DOI: 10.1146/annurev-genom-083118-015324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
23 Golán I, Rodríguez de la Fuente L, Costoya JA. NK Cell-Based Glioblastoma Immunotherapy. Cancers (Basel) 2018;10:E522. [PMID: 30567306 DOI: 10.3390/cancers10120522] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
24 Чертенко ТМ. Histological and Immunohistological Features of Reccurences in Patients with High Grade Diffuse Astrocytic Tumors. СМ 2018;0:110-116. [DOI: 10.30841/2307-5112.4.2018.163293] [Reference Citation Analysis]
25 Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M, Sorg RV. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials 2018;19:293. [PMID: 29801515 DOI: 10.1186/s13063-018-2659-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
26 Guadagno E, Presta I, Maisano D, Donato A, Pirrone CK, Cardillo G, Corrado SD, Mignogna C, Mancuso T, Donato G, Del Basso De Caro M, Malara N. Role of Macrophages in Brain Tumor Growth and Progression. Int J Mol Sci 2018;19:E1005. [PMID: 29584702 DOI: 10.3390/ijms19041005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 16.0] [Reference Citation Analysis]
27 Quezada C, Torres Á, Niechi I, Uribe D, Contreras-Duarte S, Toledo F, San Martín R, Gutiérrez J, Sobrevia L. Role of extracellular vesicles in glioma progression. Mol Aspects Med 2018;60:38-51. [PMID: 29222067 DOI: 10.1016/j.mam.2017.12.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
28 Chistiakov DA, Chekhonin IV, Chekhonin VP. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. European Journal of Pharmacology 2017;810:70-82. [DOI: 10.1016/j.ejphar.2017.05.064] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
29 Cheng Z, Zhang D, Gong B, Wang P, Liu F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget 2017;8:87244-62. [PMID: 29152078 DOI: 10.18632/oncotarget.20244] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
30 Chitadze G, Flüh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M, Bhat J, Wesch D, Oberg HH, Luecke S, Janssen O, Synowitz M, Held-Feindt J, Kabelitz D. In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. Oncoimmunology 2017;6:e1358839. [PMID: 29147621 DOI: 10.1080/2162402X.2017.1358839] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
31 Schiffer D, Mellai M, Bovio E, Annovazzi L. The neuropathological basis to the functional role of microglia/macrophages in gliomas. Neurol Sci 2017;38:1571-7. [PMID: 28593528 DOI: 10.1007/s10072-017-3002-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
32 Liu D, Tian S, Zhang K, Xiong W, Lubaki NM, Chen Z, Han W. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein Cell 2017;8:861-77. [PMID: 28488245 DOI: 10.1007/s13238-017-0415-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
33 Hao W, Luo W, Bai M, Li J, Bai X, Guo J, Wu J, Wang M. MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2. J Mol Neurosci 2016;60:531-8. [PMID: 27558109 DOI: 10.1007/s12031-016-0824-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]